Gilead Sciences has formed a cancer research collaboration with Yale School of Medicine under the terms of which it will provide US$40 M in research support and basic science infrastructure development over 4 years. The collaboration may be renewed for up to 10 years and total research funding could reach US$100 M. The research agreement will focus on the discovery of novel targeted cancer therapies and Gilead will have the first option to license any Yale inventions that result from the collaboration.